JP2013544838A - 網膜の疾患を治療するための方法 - Google Patents
網膜の疾患を治療するための方法 Download PDFInfo
- Publication number
- JP2013544838A JP2013544838A JP2013542043A JP2013542043A JP2013544838A JP 2013544838 A JP2013544838 A JP 2013544838A JP 2013542043 A JP2013542043 A JP 2013542043A JP 2013542043 A JP2013542043 A JP 2013542043A JP 2013544838 A JP2013544838 A JP 2013544838A
- Authority
- JP
- Japan
- Prior art keywords
- retinal
- retinal pigment
- compound
- blue light
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000017442 Retinal disease Diseases 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 16
- 206010038848 Retinal detachment Diseases 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 230000004264 retinal detachment Effects 0.000 claims description 10
- 230000002207 retinal effect Effects 0.000 claims description 9
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 7
- 239000000790 retinal pigment Substances 0.000 claims description 6
- 208000001344 Macular Edema Diseases 0.000 claims description 5
- 208000034247 Pattern dystrophy Diseases 0.000 claims description 5
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 230000036542 oxidative stress Effects 0.000 claims description 5
- 206010025415 Macular oedema Diseases 0.000 claims description 4
- 206010038821 Retinal anomaly congenital Diseases 0.000 claims description 4
- 201000008615 cone dystrophy Diseases 0.000 claims description 4
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 4
- 201000010230 macular retinal edema Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000016624 Retinal neoplasm Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000032398 Retinal pigment epitheliopathy Diseases 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract description 30
- 229960005017 olanzapine Drugs 0.000 abstract description 27
- 238000011282 treatment Methods 0.000 abstract description 15
- 229960004170 clozapine Drugs 0.000 abstract description 7
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 abstract description 7
- 239000002207 metabolite Substances 0.000 abstract description 5
- JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 abstract description 3
- 208000002780 macular degeneration Diseases 0.000 description 22
- 210000001525 retina Anatomy 0.000 description 22
- 241000700159 Rattus Species 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 14
- 208000035719 Maculopathy Diseases 0.000 description 13
- 201000004569 Blindness Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 206010038923 Retinopathy Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000004393 visual impairment Effects 0.000 description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 description 6
- 210000003161 choroid Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- 208000007135 Retinal Neovascularization Diseases 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000004300 dark adaptation Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 238000012014 optical coherence tomography Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 4
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- 201000007737 Retinal degeneration Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 238000013532 laser treatment Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 208000001351 Epiretinal Membrane Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 2
- 206010058490 Hyperoxia Diseases 0.000 description 2
- 208000031471 Macular fibrosis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 2
- 102000004330 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 208000027073 Stargardt disease Diseases 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- CXGXDTSWFKGIHD-CLCIBRLLSA-N [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylate Chemical compound CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CXGXDTSWFKGIHD-CLCIBRLLSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 201000007917 background diabetic retinopathy Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108091005996 glycated proteins Proteins 0.000 description 2
- 230000000222 hyperoxic effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229960004791 tropicamide Drugs 0.000 description 2
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 2
- FHPIXVHJEIZKJW-UHFFFAOYSA-N 4'-N-desmethylolanzapine Chemical compound S1C(C)=CC2=C1NC1=CC=CC=C1N=C2N1CCNCC1 FHPIXVHJEIZKJW-UHFFFAOYSA-N 0.000 description 1
- APOMSSAGEAOUGO-UHFFFAOYSA-N 8-chloro-6-(4-methylpiperazin-1-yl)-11h-benzo[b][1,4]benzodiazepine Chemical group C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=CC=C(Cl)C=C12 APOMSSAGEAOUGO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102100022794 Bestrophin-1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 description 1
- 208000032400 Retinal pigmentation Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036956 Usher syndrome type 1B Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000011685 brown norway rat Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- LJVNYCDXBXGQIK-UHFFFAOYSA-N chembl440512 Chemical compound S1C(C)=CC2=C1NC1=CC=CC=C1N=C2N1CC[N+](C)([O-])CC1 LJVNYCDXBXGQIK-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000012792 core layer Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- -1 monoalkyl Chemical class 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000020939 vitelliform macular dystrophy 1 Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940039925 zyprexa Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41966010P | 2010-12-03 | 2010-12-03 | |
| US61/419,660 | 2010-12-03 | ||
| PCT/US2011/061370 WO2012074788A1 (en) | 2010-12-03 | 2011-11-18 | Methods for treating diseases of the retina |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013544838A true JP2013544838A (ja) | 2013-12-19 |
| JP2013544838A5 JP2013544838A5 (https=) | 2015-01-15 |
Family
ID=45507856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542043A Pending JP2013544838A (ja) | 2010-12-03 | 2011-11-18 | 網膜の疾患を治療するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9018202B2 (https=) |
| EP (1) | EP2646034A1 (https=) |
| JP (1) | JP2013544838A (https=) |
| KR (1) | KR20130122958A (https=) |
| CN (1) | CN103327981A (https=) |
| AU (1) | AU2011336976A1 (https=) |
| BR (1) | BR112013013636A2 (https=) |
| CA (1) | CA2819616A1 (https=) |
| RU (1) | RU2013129748A (https=) |
| WO (1) | WO2012074788A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022163086A (ja) * | 2017-07-06 | 2022-10-25 | 健一 山田 | 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| EP3919052A4 (en) * | 2019-01-09 | 2022-10-05 | Fuso Pharmaceutical Industries, Ltd. | Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases |
| US20250170143A1 (en) * | 2022-04-14 | 2025-05-29 | Mayo Foundation For Medical Education And Research | Methods of treating ocular fibrotic pathologies |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10175865A (ja) * | 1996-12-11 | 1998-06-30 | Towa Rin | 抗眼圧活性製剤 |
| WO2004103263A2 (en) * | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
| JP2006515628A (ja) * | 2003-01-23 | 2006-06-01 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 |
| JP2008509147A (ja) * | 2004-08-05 | 2008-03-27 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 |
| WO2008111497A1 (ja) * | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| JP2010523651A (ja) * | 2007-04-12 | 2010-07-15 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤／調節剤のｎ−オキシド誘導体及び／又はジ−ｎ−オキシド誘導体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1004520A1 (en) | 1992-05-13 | 1998-11-27 | Novartis Ag | Ophthalmic compositions containing a cyclosporin |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| US5631250A (en) | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
| US5744468A (en) * | 1996-10-23 | 1998-04-28 | Tong-Ho Lin | Hypotensive intraocular pressure activity of clozapine and sulpiride |
| US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| JP2002530340A (ja) * | 1998-11-23 | 2002-09-17 | セプラコール， インク． | オランザピン−ｎ−オキサイドを含む医薬組成物 |
| DE10206941A1 (de) | 2002-02-19 | 2003-09-25 | Goetz Nowak | Neue Arzneimittel |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US20060035887A1 (en) | 2004-07-02 | 2006-02-16 | Dr. Reddy's Laboratories Limited | Process for preparing olanzapine |
| CN101437478A (zh) * | 2004-10-04 | 2009-05-20 | Qlt美国有限公司 | 聚合送递制剂的眼部送递 |
| MX2007003789A (es) | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
| US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
-
2011
- 2011-11-16 US US13/298,028 patent/US9018202B2/en active Active
- 2011-11-18 WO PCT/US2011/061370 patent/WO2012074788A1/en not_active Ceased
- 2011-11-18 CA CA 2819616 patent/CA2819616A1/en not_active Abandoned
- 2011-11-18 JP JP2013542043A patent/JP2013544838A/ja active Pending
- 2011-11-18 KR KR20137017036A patent/KR20130122958A/ko not_active Ceased
- 2011-11-18 BR BR112013013636A patent/BR112013013636A2/pt not_active IP Right Cessation
- 2011-11-18 EP EP11810917.2A patent/EP2646034A1/en not_active Withdrawn
- 2011-11-18 RU RU2013129748/15A patent/RU2013129748A/ru not_active Application Discontinuation
- 2011-11-18 CN CN2011800652550A patent/CN103327981A/zh active Pending
- 2011-11-18 AU AU2011336976A patent/AU2011336976A1/en not_active Abandoned
-
2015
- 2015-04-27 US US14/696,789 patent/US9561234B2/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10175865A (ja) * | 1996-12-11 | 1998-06-30 | Towa Rin | 抗眼圧活性製剤 |
| JP2006515628A (ja) * | 2003-01-23 | 2006-06-01 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用 |
| WO2004103263A2 (en) * | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
| JP2008509147A (ja) * | 2004-08-05 | 2008-03-27 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 |
| WO2008111497A1 (ja) * | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| JP2010523651A (ja) * | 2007-04-12 | 2010-07-15 | エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ | 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤／調節剤のｎ−オキシド誘導体及び／又はジ−ｎ−オキシド誘導体 |
Non-Patent Citations (1)
| Title |
|---|
| メルクマニュアル 第18版 日本語版, vol. 第３刷, JPN6015042705, 25 April 2007 (2007-04-25), pages ９４４頁, ISSN: 0003181754 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022163086A (ja) * | 2017-07-06 | 2022-10-25 | 健一 山田 | 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法 |
| US12306164B2 (en) | 2017-07-06 | 2025-05-20 | Ken-Ichi Yamamada | Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103327981A (zh) | 2013-09-25 |
| US9018202B2 (en) | 2015-04-28 |
| CA2819616A1 (en) | 2012-06-07 |
| AU2011336976A1 (en) | 2013-07-11 |
| US9561234B2 (en) | 2017-02-07 |
| BR112013013636A2 (pt) | 2016-11-08 |
| EP2646034A1 (en) | 2013-10-09 |
| RU2013129748A (ru) | 2015-01-10 |
| WO2012074788A1 (en) | 2012-06-07 |
| KR20130122958A (ko) | 2013-11-11 |
| US20150290215A1 (en) | 2015-10-15 |
| US20120142675A1 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cheng et al. | Ocular disease therapeutics: design and delivery of drugs for diseases of the eye | |
| JP2020536067A (ja) | 眼の状態を処置するための組成物および方法 | |
| US9561234B2 (en) | Methods for treating diseases of the retina | |
| AU2024200866A1 (en) | Compositions and methods for treating ocular pathologies | |
| US10716750B2 (en) | Topical ophthalmic formulations of endothelin receptor antagonists | |
| JP2013510852A (ja) | フルオレノン誘導体による眼の病態の治療 | |
| US20230372311A1 (en) | Compositions and methods of treating age-related retinal dysfunction | |
| KR20170094552A (ko) | 약학적 조성물 및 이의 용도 | |
| CN107249577A (zh) | 用于治疗青光眼的组合物和方法 | |
| WO2011097577A2 (en) | Compositions and methods for treating or preventing retinal degeneration | |
| JP2009519962A (ja) | 眼投与用局所メカミルアミン製剤およびその使用 | |
| US20130316983A1 (en) | Drug screening method, compositions and methods of treating glaucoma | |
| EP4141019A1 (en) | Peptide fh and its use in preparation of drugs for treating and preventing ocular fundus vascular diseases | |
| CN116650461A (zh) | 咖啡酸苯乙酯滴及其眼液在制备治疗糖尿病视网膜病变药物中的应用 | |
| CA2888984A1 (en) | Methods for treating eye disorders | |
| WO2006098292A1 (ja) | 眼疾患治療剤 | |
| WO2026078034A1 (en) | Sitagliptin for use in retinal diseases with neovascularization | |
| JP2014533732A (ja) | 網膜神経保護のための７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロ−キノリンを含む医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141118 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151026 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160126 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160627 |